The constipation market place is crowded and getting more competitive each and every day. It includes some of the biggest names in biotech including Salix (NASDAQ:SLXP); Cubist, recently acquired by Merck (NYSE:MRK); AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), not to mention a handful of hungry upstarts. However, it's not the presence of competition but the steady drum beat of news surrounding their products - all positive of late, that has caused Synergy to fall further behind in the lens of investor perception. Each time a news story breaks, Synergy's entrance into the market fray appears further and further away.
The Baker Brothers have lost 44.6% of their confidence.
That glass half-empty perspective means they've retained 55.4% of their optimism. But the fact remains that Baker Bros Advisors LLC, famous for their biotechnology sector holdings have liquidated 785k Synergy shares, retaining 973k. They're currently $4,446,000 underwater.
Haven't heard hide nor hare from him..
be able to unload due to full capacity of the land based tanks, and they will simply anchor off shore.
Zero institutional support..
Seen it before.. Should have bailed at $4.68
shares than Vanguard and Fidelity if we can believe your stories, LOL...
So it seems to many here..
That is all I can say..
The market says this is a DOG. SCMP rules this space..